Document Detail

Nicergoline increases serum substance P levels in patients with an ischaemic stroke.
MedLine Citation:
PMID:  20029189     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Aspiration pneumonia is one of the most important complications following ischaemic stroke, and a leading cause of mortality in stroke patients. This is particularly prevalent in patients with involvement of the basal ganglia, which may be due to impaired neurotransmission through lack of production of substance P. METHODS: Consecutive patients in the chronic stage, 1-3 months after cerebral ischaemic infarction, were assessed for basal ganglia involvement by magnetic resonance imaging. The patients were randomised to 4 weeks of treatment with (n = 25) or without (n = 25) nicergoline (15 mg t.i.d.). Serum concentration of substance P was measured by radioimmunoassay. RESULTS: At entry to the study, mean concentration of substance P was significantly (p < 0.001) lower in patients with bilateral basal ganglia lesions than in patients with no or unilateral basal ganglia involvement. Nicergoline administration caused a significant (p = 0.021) increase from baseline in mean substance P concentration. No significant change was seen in the nicergoline-untreated patients (p = 0.626). Among the patients who received nicergoline, 11 patients had bilateral basal ganglia involvement and there was no significant mean change in substance P in these patients, whereas there was a significant increase (p = 0.032) in the 14 nicergoline-treated patients with no or unilateral basal ganglia involvement. CONCLUSIONS: The present study suggests a possible effect of nicergoline to increase substance P level in ischaemic stroke patients with partial damage to basal ganglia, who have a decreased swallowing response and consequent risk of aspiration pneumonia. Further trials of nicergoline treatment in patients at risk for aspiration pneumonia are warranted.
Yasuhiro Nishiyama; Arata Abe; Masayuki Ueda; Ken-ichiro Katsura; Yasuo Katayama
Related Documents :
4001309 - The natural history of asymptomatic extracranial arterial disease.
14557569 - Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy.
17272899 - Hyperacute thrombolysis with iv rtpa of acute ischemic stroke: efficacy and safety prof...
12154259 - Prevalence and predictors of upper airway obstruction in the first 24 hours after acute...
18173959 - Antiplatelet therapy for stroke prevention.
14584489 - Design and baseline characteristics of the stroke prevention by aggressive reduction in...
9342009 - Relation between lipoprotein(a) concentrations in patients with acute-phase response an...
3073809 - Sputum wax-worms after plombage.
436859 - Hydrocephalus after subarachnoid bleeding. a correlation of clinical findings, the resu...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2009-12-18
Journal Detail:
Title:  Cerebrovascular diseases (Basel, Switzerland)     Volume:  29     ISSN:  1421-9786     ISO Abbreviation:  Cerebrovasc. Dis.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-01-21     Completed Date:  2010-03-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100851     Medline TA:  Cerebrovasc Dis     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  194-8     Citation Subset:  IM    
Copyright Information:
(c) 2009 S. Karger AG, Basel.
Division of Neurology, Nephrology and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan. nomo16 @
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Basal Ganglia / drug effects*,  metabolism,  pathology
Biological Markers / blood
Brain Ischemia / blood,  complications,  drug therapy*,  pathology
Central Nervous System Agents / therapeutic use*
Deglutition / drug effects
Magnetic Resonance Imaging
Nicergoline / therapeutic use*
Pneumonia, Aspiration / blood,  etiology,  prevention & control
Stroke / blood,  drug therapy*,  etiology,  pathology
Substance P / blood*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Biological Markers; 0/Central Nervous System Agents; 27848-84-6/Nicergoline; 33507-63-0/Substance P

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Modified Rankin Scale in Acute Stroke Has Good Inter-Rater-Reliability but Questionable Validity...
Next Document:  Spatial Distension Variations Are Associated with Focal Atherosclerotic Plaques.